KUALA LUMPUR, Oct 28 (Bernama) -- Japanese hotel operator, Pacifica Hotels G.K. has signed a franchise agreement with Marriott International to open a Courtyard by Marriott hotel in Takayama, Gifu prefecture, in autumn 2028.
The hotel operator in a statement said the 207-room Courtyard by Marriott Hida Takayama will be a short walk from Takayama Station and close proximity to the city’s main street, historical attractions and restaurants.
Takayama is known for its Edo-period architecture and traditions, listed by UNESCO as intangible cultural heritage, and is near the UNESCO World Heritage-listed village of Shirakawa-go.
“Takayama is one of my personal favourite tourist destinations in Japan. It has the best collection of Edo period structures anywhere I have seen in Japan, wonderful food and is a great base for numerous day trips such as Shirakawa-go and Kamikochi,” said Pacifica Hotels G.K. chief executive officer, Seth Sulkin.
The hotel will include flexible spaces for work and relaxation, and an all-day dining restaurant with semi-open kitchens serving Japanese and international cuisine.
Pacifica, which operates hotels under Marriott International and IHG brands, will also open Courtyard by Marriott Hiroshima in autumn 2027 and Westin Hokkaido Furano Resort in spring 2029.
-- BERNAMA
Wednesday, October 28, 2026
WEALTHY FAMILIES DIVERSIFY RESIDENCE, CITIZENSHIP OPTIONS AMID GLOBAL VOLATILITY
KUALA LUMPUR, Oct 28 (Bernama) -- Henley & Partners’ new data showed a rising interest in additional residence and citizenship rights among wealthy families in some of the world’s most established countries, as political, regulatory and social volatility sharpened the focus on resilience and future optionality.
To date this year, the company has assisted clients from over 100 nationalities across 50-plus residence and citizenship country options, with more than a third of applicants already living outside their countries of origin.
“Families have long understood the value of diversifying their investments; increasingly, they are applying the same principle to where they have the right to live, work and build their lives,” said Henley & Partners chief executive officer, Dr Juerg Steffen.
According to Henley & Partners in a statement, the changing geography of demand is particularly striking. United States (US) nationals remain the firm’s largest source nationality, while the United Kingdom ranks sixth and Germany 10th.
Meanwhile, France has risen from 36th to 14th among source nationalities, and Australia and Canada are also now in the top 15, highlighting the growing prominence of clients from highly developed economies who already enjoy considerable international mobility.
Henley & Partners added that applications from French nationals were already close to matching the full-year 2025 figure by the end of the third quarter, while Italian applications had surpassed last year's level. Enquiries from both countries also recorded increases.
The US trend remains the most pronounced, with applications from Americans rising 52 per cent over the past 18 months compared with the preceding 18-month period, yet only nine per cent of US applicants actually reside outside the country.
According to the firm’s latest client data, US nationals have applied for 27 different residence and citizenship country options in 2026 across Europe, the Caribbean, Latin America and Asia-Pacific.
French and Italian applicants are similarly securing access rights to multiple jurisdictions rather than converging on a single alternative destination. Half of Italian applicants still reside in Italy, while most French applicants already live outside France, the firm added.
Henley & Partners will explore these themes at its 20th Global Citizenship Conference in Zurich from Nov 23 to 25.
-- BERNAMA
To date this year, the company has assisted clients from over 100 nationalities across 50-plus residence and citizenship country options, with more than a third of applicants already living outside their countries of origin.
“Families have long understood the value of diversifying their investments; increasingly, they are applying the same principle to where they have the right to live, work and build their lives,” said Henley & Partners chief executive officer, Dr Juerg Steffen.
According to Henley & Partners in a statement, the changing geography of demand is particularly striking. United States (US) nationals remain the firm’s largest source nationality, while the United Kingdom ranks sixth and Germany 10th.
Meanwhile, France has risen from 36th to 14th among source nationalities, and Australia and Canada are also now in the top 15, highlighting the growing prominence of clients from highly developed economies who already enjoy considerable international mobility.
Henley & Partners added that applications from French nationals were already close to matching the full-year 2025 figure by the end of the third quarter, while Italian applications had surpassed last year's level. Enquiries from both countries also recorded increases.
The US trend remains the most pronounced, with applications from Americans rising 52 per cent over the past 18 months compared with the preceding 18-month period, yet only nine per cent of US applicants actually reside outside the country.
According to the firm’s latest client data, US nationals have applied for 27 different residence and citizenship country options in 2026 across Europe, the Caribbean, Latin America and Asia-Pacific.
French and Italian applicants are similarly securing access rights to multiple jurisdictions rather than converging on a single alternative destination. Half of Italian applicants still reside in Italy, while most French applicants already live outside France, the firm added.
Henley & Partners will explore these themes at its 20th Global Citizenship Conference in Zurich from Nov 23 to 25.
-- BERNAMA
Tuesday, October 27, 2026
STRONG AND TRUSTED ACCOUNTANCY PROFESSION KEY TO MOVING MALAYSIAN BUSINESSES UP THE VALUE CHAIN, SAYS DEPUTY MINISTER OF FINANCE YB LIEW CHIN TONG
,%20signing%20the%20guest%20book,%20witnessed%20by%20MIA%20Vice%20President%20Ahmad%20Syahazan%20Yaacob.jpg) |
| YB Liew Chin Tong, Deputy Minister of Finance (seated), signing the guest book, witnessed by MIA Vice President Ahmad Syahazan Yaacob |
,%20together%20with%20representatives%20from%20Jabatan%20Akauntan%20Negara%20Malaysia%20(JANM)%20and%20MIA.jpg) |
| YB Liew Chin Tong, Deputy Minister of Finance (seated centre), together with representatives from Jabatan Akauntan Negara Malaysia (JANM) and MIA |
KUALA LUMPUR, Oct 27 (Bernama) -- As Malaysia seeks to move into higher-value economic activities, the accountancy profession is central to helping businesses strengthen financial management, governance and risk oversight, and make better-informed strategic decisions.
“Moving up the value chain requires businesses to allocate capital effectively, manage risks, strengthen governance and make informed decisions about growth. Accountancy professionals play an important role by supporting reliable financial information, sound governance and accountability. These are essential to building the trust that enables businesses to attract investment, pursue higher-value opportunities and compete effectively. Trust is the profession’s foundation and a competitive advantage for Malaysia,” said Deputy Minister of Finance YB Liew Chin Tong during a courtesy visit to the headquarters of the Malaysian Institute of Accountants (MIA) in Bangsar South, where he engaged with MIA leadership on the role of the profession in governance and nation building.
While the accountancy profession plays a critical role, the integrity of Malaysia’s financial reporting ecosystem ultimately depends on every participant discharging their respective responsibilities. “The strength of Malaysia’s financial reporting ecosystem depends on strategic collaboration and a shared commitment to accountability, competence and integrity. By working together to uphold high standards of financial reporting and governance, particularly among large organisations, we can strengthen public confidence, safeguard economic resilience and contribute to the nation’s sustainable growth,”said MIA Vice President Ahmad Syahazan Yaacob.
Future-Readiness Underpins Capability Building and Trust
Ensuring the future-readiness of the profession is equally important to strengthening professional judgement and building capabilities to uphold integrity and trust. Towards this end, MIA—as the statutory body mandated under the Accountants Act 1967 to regulate and develop the accountancy profession—is actively engaging the Ministry of Finance on amendments to the Act to shape an enabling ecosystem for accountancy professionals and better protect the public interest.
“A future-ready accountancy profession anchored in ethics and integrity is essential to Malaysia’s economic ambitions. By strengthening business capabilities, upholding professional judgement and building trust in financial and corporate information, accountants can help businesses compete more effectively and support the nation’s long-term economic growth,” said Ahmad Syahazan.
MIA prioritises talent development as a key component of future readiness and holistic national competitiveness. As businesses pursue growth and more complex activities, demand is projected to increase for professional services in areas such as tax advisory, funding readiness, business transformation, sustainability reporting, governance and risk management. MIA is strengthening the profession’s talent pipeline and capabilities through education, professional development and training initiatives.
Reinforcing the importance of developing a competent and future-ready accountancy profession, YB Liew also emphasised the critical role of ethics and integrity in strengthening governance and safeguarding public trust. “Corruption and money laundering undermine public trust, weaken national institutions, distort economic development, and threaten the nation’s long-term prosperity. Addressing these challenges requires highly competent accountancy professionals who demonstrate the highest standards of ethics, integrity, independence, and professionalism”.
“Equally important is a robust regulatory framework that ensures accountability, enforces compliance, and upholds professional standards. Together, ethical and competent accountants and effective regulatory mechanisms form a critical line of defence against financial misconduct, protecting the public, strengthening national governance, and preserving the nation’s economic stability and reputation”, he said.
SOURCE: Malaysian Institute of Accountants (MIA)
FOR MORE INFORMATION, PLEASE CONTACT:
MIA STRATEGIC COMMUNICATIONS & BRANDING
E-mail: communications@mia.org.my
Name: THANE MEYYAPPAN
Tel: +6012 248 9534
Name: MOHD FAIZ OTHMAN
Tel: +6012 622 5027
--BERNAMA
FOREIGN DIPLOMATS TOUR HANGZHOU’S ANCIENT RUINS, TECH HUBS AND UNIVERSITY
KUALA LUMPUR, Oct 27 (Bernama) -- Diplomats from Chile, Colombia, Ethiopia, Kazakhstan and Iraq toured Hangzhou in east China from Oct 17 to 19, visiting an ancient archaeological site, technology exhibitions and a university.
According to a statement, the delegation was invited by Haiwainet, part of People’s Daily, as part of the Zhejiang Tour for diplomatic envoys.
Chile’s Ambassador to China, Alfonso Silva said he was impressed by the Liangzhu civilisation and described the site as “a great heritage of which the Chinese people must be proud”.
The visit began on Oct 17 at the Archaeological Ruins of Liangzhu City, which marks the 90th anniversary of its discovery this year. At the Liangzhu Museum and the Liangzhu Archaeological Site Park, the diplomats viewed jade cong, stone yue axes, earthen embankments and rice fields from the 5,000-year-old civilisation.
On Oct 18, the delegation visited exhibitions in Hangzhou’s new urban centre featuring local technology companies, including those known as the “Six Little Dragons” and the “New Eight Steeds”. The diplomats tried augmented reality glasses and played Gomoku, a traditional five-in-a-row board game, against artificial intelligence.
On Oct 19, at Zhejiang International Studies University, the diplomats viewed folk-art exhibits, tried Chinese calligraphy and made Chongyang cakes, a traditional snack for the Double Ninth Festival. They also met students to exchange views on cultural understanding.
The tour was guided by the Information Office of the Zhejiang Provincial People’s Government and the Zhejiang Provincial Department of Culture, Radio, Television and Tourism.
It was organised by the Zhejiang International Communication Center, with support from People’s Daily Haiwainet, the Hangzhou bureau of Zhejiang Daily Press Group and the university.
-- BERNAMA
According to a statement, the delegation was invited by Haiwainet, part of People’s Daily, as part of the Zhejiang Tour for diplomatic envoys.
Chile’s Ambassador to China, Alfonso Silva said he was impressed by the Liangzhu civilisation and described the site as “a great heritage of which the Chinese people must be proud”.
The visit began on Oct 17 at the Archaeological Ruins of Liangzhu City, which marks the 90th anniversary of its discovery this year. At the Liangzhu Museum and the Liangzhu Archaeological Site Park, the diplomats viewed jade cong, stone yue axes, earthen embankments and rice fields from the 5,000-year-old civilisation.
On Oct 18, the delegation visited exhibitions in Hangzhou’s new urban centre featuring local technology companies, including those known as the “Six Little Dragons” and the “New Eight Steeds”. The diplomats tried augmented reality glasses and played Gomoku, a traditional five-in-a-row board game, against artificial intelligence.
On Oct 19, at Zhejiang International Studies University, the diplomats viewed folk-art exhibits, tried Chinese calligraphy and made Chongyang cakes, a traditional snack for the Double Ninth Festival. They also met students to exchange views on cultural understanding.
The tour was guided by the Information Office of the Zhejiang Provincial People’s Government and the Zhejiang Provincial Department of Culture, Radio, Television and Tourism.
It was organised by the Zhejiang International Communication Center, with support from People’s Daily Haiwainet, the Hangzhou bureau of Zhejiang Daily Press Group and the university.
-- BERNAMA
SMARTKARGO LAUNCHES FOUR AI APPS FOR AIRLINE CARGO OPERATIONS
KUALA LUMPUR, Oct 27 (Bernama) -- Cloud-based logistics platform SmartKargo has launched four artificial intelligence (AI) applications for airlines, designed to help increase revenue, cut costs and reduce risk in their cargo operations.
The apps are delivered through application programming interfaces (APIs) and run on top of an airline’s existing cargo management system, whether commercial or built in-house, so no system migration is required. The company said the apps are modular and can go live within weeks.
“At SmartKargo, we start with something far more useful than hype: a business question. These apps are not a research project or a roadmap slide,” said SmartKargo Chief Revenue Officer, Olivier Houri adding that they were built to plug into whatever cargo system an airline already runs and grow with.
In a statement, the company said it tests every capability against those goals before building or deploying it.
The AIRCAM app forecasts capacity, predicts demand and recommends dynamic spot rates in real time, helping cargo teams optimise pricing and capacity on each flight and route. The AINOC app gives operations teams a single, predictive view of their network to spot problems before they cause delays.
The AIULD app tracks and forecasts the location, condition and availability of unit load devices (ULDs), while the AICTX app connects cargo systems and partners through a single, standards-based messaging layer.
The apps are available now to airlines using any major cargo management system, and carriers can adopt one app or the full set.
SmartKargo said it would continue to expand the range, adding new applications and deepening existing ones based on the problems airlines raise.
-- BERNAMA
The apps are delivered through application programming interfaces (APIs) and run on top of an airline’s existing cargo management system, whether commercial or built in-house, so no system migration is required. The company said the apps are modular and can go live within weeks.
“At SmartKargo, we start with something far more useful than hype: a business question. These apps are not a research project or a roadmap slide,” said SmartKargo Chief Revenue Officer, Olivier Houri adding that they were built to plug into whatever cargo system an airline already runs and grow with.
In a statement, the company said it tests every capability against those goals before building or deploying it.
The AIRCAM app forecasts capacity, predicts demand and recommends dynamic spot rates in real time, helping cargo teams optimise pricing and capacity on each flight and route. The AINOC app gives operations teams a single, predictive view of their network to spot problems before they cause delays.
The AIULD app tracks and forecasts the location, condition and availability of unit load devices (ULDs), while the AICTX app connects cargo systems and partners through a single, standards-based messaging layer.
The apps are available now to airlines using any major cargo management system, and carriers can adopt one app or the full set.
SmartKargo said it would continue to expand the range, adding new applications and deepening existing ones based on the problems airlines raise.
-- BERNAMA
HUAYAN ROBOTICS TO SHOWCASE HUMANOID ROBOTIC ARM AT ROBOTWORLD 2026
KUALA LUMPUR, Oct 27 (Bernama) -- Huayan Robotics will showcase a seven-axis humanoid robotic arm alongside automation solutions for welding, palletising and machine tending at Robotworld 2026, to be held in Goyang, South Korea, from Nov 4 to 7.
The company will exhibit at the KINTEX exhibition centre and will also display core motion components for embodied artificial intelligence (AI), the technology that allows robots to sense and act in the physical world.
The robotic arm is designed for integration into humanoid and other embodied robotic platforms, combining force control in every joint with internal cable routing and native support for the Robot Operating System 2 (ROS 2). Its open development interfaces allow developers to connect it with other hardware and software systems.
According to the company in a statement, the components on show include humanoid joint modules, frameless motors and high-precision XYZ motion stages.
The welding system is built around the company’s E12-Pro collaborative robot, which has a 1.8-metre reach, and includes a dual-axis positioner to improve access to large and complex workpieces. Laser seam tracking and automatic path correction help produce consistent welds along complex seams while reducing manual adjustments.
For palletising, the company’s S Series robots can handle payloads of up to 60-kilogramme. They feature vision-assisted positioning and configurable pallet patterns, and are aimed at consumer goods manufacturing, food processing and warehouse logistics.
Huayan’s Elfin and Elfin-Pro collaborative robots automate the loading and unloading of computer numerical control (CNC) machines, with a maximum reach of 1.8 metres and protection ratings of up to IP66. The company said they can improve cycle times by up to 50 per cent.
Huayan Robotics develops collaborative robots, motion components and embodied AI systems, serving customers in more than 50 countries and regions.
-- BERNAMA
The company will exhibit at the KINTEX exhibition centre and will also display core motion components for embodied artificial intelligence (AI), the technology that allows robots to sense and act in the physical world.
The robotic arm is designed for integration into humanoid and other embodied robotic platforms, combining force control in every joint with internal cable routing and native support for the Robot Operating System 2 (ROS 2). Its open development interfaces allow developers to connect it with other hardware and software systems.
According to the company in a statement, the components on show include humanoid joint modules, frameless motors and high-precision XYZ motion stages.
The welding system is built around the company’s E12-Pro collaborative robot, which has a 1.8-metre reach, and includes a dual-axis positioner to improve access to large and complex workpieces. Laser seam tracking and automatic path correction help produce consistent welds along complex seams while reducing manual adjustments.
For palletising, the company’s S Series robots can handle payloads of up to 60-kilogramme. They feature vision-assisted positioning and configurable pallet patterns, and are aimed at consumer goods manufacturing, food processing and warehouse logistics.
Huayan’s Elfin and Elfin-Pro collaborative robots automate the loading and unloading of computer numerical control (CNC) machines, with a maximum reach of 1.8 metres and protection ratings of up to IP66. The company said they can improve cycle times by up to 50 per cent.
Huayan Robotics develops collaborative robots, motion components and embodied AI systems, serving customers in more than 50 countries and regions.
-- BERNAMA
Friday, October 23, 2026
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia
Highlights
Highlights
- Collaboration aims to accelerate precision oncology research in Australia
- Combines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program
- Together, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-driven clinical trials
DURHAM, N.C. and SYDNEY, Oct 23 (Bernama-GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), and Omico, Australia’s leading precision oncology screening and trial matching organization, today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarker-matched clinical trials. By combining Omico's precision oncology network with Fortrea's scientific and clinical trial experience, the joint effort aims to improve study planning, site selection and patient recruitment to expand access to biomarker-driven oncology research globally.
Through this initiative, Omico will support Fortrea’s clients in their oncology drug development needs by providing access to patient population insights, including genomic profiling, trial-matching capabilities, real-world oncology data and patient referral pathways in Australia, a key country both for early and late phase Oncology clinical research activities. The collaboration will combine Fortrea’s oncology drug development experience with Omico’s flagship Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program, the largest cancer genomics initiative in Australia. PrOSPeCT is designed to provide molecular profiling and help match patients to biomarker-driven clinical trials and targeted therapies.
“Our collaboration with Omico is about seeking to reach the right patient for the right study as quickly as possible,” said Oren Cohen, M.D., Chief Medical Officer at Fortrea. “Modern oncology development demands ever-greater precision to match specific cancers with the therapies most likely to benefit patients, and to do so as quickly as possible. Our work with Omico accelerates our ability to identify the right patients for biomarker-driven studies in Australia and help advance precision medicine for people with cancer.”
Omico has built one of Australia's most extensive precision oncology ecosystems, combining molecular profiling, real-world evidence, cohort research programs and a nationwide network of investigators and clinical sites. Omico has reported more than 23,000 consented patients within its clinic-genomic databases and has received referrals from more than 1,600 clinicians across Australia.
“Australia is well positioned to support global biomarker-driven clinical trials, through Omico’s established national precision oncology research infrastructure, expertise and networks,” said Professor David Thomas, Chief Science and Strategy Officer at Omico. “By combining our national data and trial matching capabilities with Fortrea’s global clinical development expertise, we can help international sponsors identify relevant patient populations, plan trials more effectively and support targeted recruitment.”
Fortrea’s oncology expertise is underpinned by thousands of operational professionals and supported by more than 50 oncology physicians on staff. This collaboration comes at a time when modern oncology drug development has accelerated the focus on precision medicine, biomarker-driven development and targeted patient identification. Working together, Fortrea and Omico can offer more efficient site selection and the ability to match patients with appropriate studies tied to their unique genomic data, enabling more people to participate in studies tailored to their specific condition in Australia.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn and X and Bluesky.
About Omico
Omico is an independent, national, not-for-profit research organisation changing the way we fight cancer. We work to improve outcomes for Australians with cancer by providing equitable access to precision oncology and translating scientific advances into clinical care and research, and generating the evidence needed to inform health policy and system reform. Working with Australia's leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government, we are accelerating molecular profiling, biomarker-led clinical trials, personalised cancer risk management and real-world evidence.
About PrOSPeCT
PrOSPeCT is Australia's largest precision oncology initiative. Delivered by Omico and a national network of healthcare, research and industry partners, it provides eligible Australians with access to molecular profiling and matching to biomarker-led clinical trials and therapies (at no cost to the patient), while generating clinical, genomic, treatment and outcomes data to advance research, improve cancer care and inform future health policy.
Fortrea Contacts:
Galen Wilson (Media) – 703-298-0802, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Omico Contact:
Kym Bramich (Communications) – +61 414 795 087, k.bramich@omico.org.au
SOURCE: Fortrea Holdings Inc
Through this initiative, Omico will support Fortrea’s clients in their oncology drug development needs by providing access to patient population insights, including genomic profiling, trial-matching capabilities, real-world oncology data and patient referral pathways in Australia, a key country both for early and late phase Oncology clinical research activities. The collaboration will combine Fortrea’s oncology drug development experience with Omico’s flagship Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program, the largest cancer genomics initiative in Australia. PrOSPeCT is designed to provide molecular profiling and help match patients to biomarker-driven clinical trials and targeted therapies.
“Our collaboration with Omico is about seeking to reach the right patient for the right study as quickly as possible,” said Oren Cohen, M.D., Chief Medical Officer at Fortrea. “Modern oncology development demands ever-greater precision to match specific cancers with the therapies most likely to benefit patients, and to do so as quickly as possible. Our work with Omico accelerates our ability to identify the right patients for biomarker-driven studies in Australia and help advance precision medicine for people with cancer.”
Omico has built one of Australia's most extensive precision oncology ecosystems, combining molecular profiling, real-world evidence, cohort research programs and a nationwide network of investigators and clinical sites. Omico has reported more than 23,000 consented patients within its clinic-genomic databases and has received referrals from more than 1,600 clinicians across Australia.
“Australia is well positioned to support global biomarker-driven clinical trials, through Omico’s established national precision oncology research infrastructure, expertise and networks,” said Professor David Thomas, Chief Science and Strategy Officer at Omico. “By combining our national data and trial matching capabilities with Fortrea’s global clinical development expertise, we can help international sponsors identify relevant patient populations, plan trials more effectively and support targeted recruitment.”
Fortrea’s oncology expertise is underpinned by thousands of operational professionals and supported by more than 50 oncology physicians on staff. This collaboration comes at a time when modern oncology drug development has accelerated the focus on precision medicine, biomarker-driven development and targeted patient identification. Working together, Fortrea and Omico can offer more efficient site selection and the ability to match patients with appropriate studies tied to their unique genomic data, enabling more people to participate in studies tailored to their specific condition in Australia.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn and X and Bluesky.
About Omico
Omico is an independent, national, not-for-profit research organisation changing the way we fight cancer. We work to improve outcomes for Australians with cancer by providing equitable access to precision oncology and translating scientific advances into clinical care and research, and generating the evidence needed to inform health policy and system reform. Working with Australia's leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government, we are accelerating molecular profiling, biomarker-led clinical trials, personalised cancer risk management and real-world evidence.
About PrOSPeCT
PrOSPeCT is Australia's largest precision oncology initiative. Delivered by Omico and a national network of healthcare, research and industry partners, it provides eligible Australians with access to molecular profiling and matching to biomarker-led clinical trials and therapies (at no cost to the patient), while generating clinical, genomic, treatment and outcomes data to advance research, improve cancer care and inform future health policy.
Fortrea Contacts:
Galen Wilson (Media) – 703-298-0802, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Omico Contact:
Kym Bramich (Communications) – +61 414 795 087, k.bramich@omico.org.au
SOURCE: Fortrea Holdings Inc
Subscribe to:
Posts (Atom)